Correlation Between Alto Neuroscience, and NewAmsterdam Pharma

Can any of the company-specific risk be diversified away by investing in both Alto Neuroscience, and NewAmsterdam Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alto Neuroscience, and NewAmsterdam Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alto Neuroscience, and NewAmsterdam Pharma, you can compare the effects of market volatilities on Alto Neuroscience, and NewAmsterdam Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alto Neuroscience, with a short position of NewAmsterdam Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alto Neuroscience, and NewAmsterdam Pharma.

Diversification Opportunities for Alto Neuroscience, and NewAmsterdam Pharma

0.45

Correlation Coefficient

Alto Neuroscience,  NewAmsterdam Pharma

Very weak diversification

The 3 months correlation between Alto and NewAmsterdam is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Alto Neuroscience, and NewAmsterdam Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NewAmsterdam Pharma and Alto Neuroscience, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alto Neuroscience, are associated (or correlated) with NewAmsterdam Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NewAmsterdam Pharma has no effect on the direction of Alto Neuroscience, i.e., Alto Neuroscience, and NewAmsterdam Pharma go up and down completely randomly.

Pair Corralation between Alto Neuroscience, and NewAmsterdam Pharma

Given the investment horizon of 90 days Alto Neuroscience, is expected to under-perform the NewAmsterdam Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Alto Neuroscience, is 1.11 times less risky than NewAmsterdam Pharma. The stock trades about -0.17 of its potential returns per unit of risk. The NewAmsterdam Pharma is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest  1,389  in NewAmsterdam Pharma on December 30, 2024 and sell it today you would lose (343.00) from holding NewAmsterdam Pharma or give up 24.69% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Alto Neuroscience,  vs.  NewAmsterdam Pharma

Alto Neuroscience,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Alto Neuroscience, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

NewAmsterdam Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Alto Neuroscience, and NewAmsterdam Pharma

The main advantage of trading using opposite Alto Neuroscience, and NewAmsterdam Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alto Neuroscience, position performs unexpectedly, NewAmsterdam Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NewAmsterdam Pharma will offset losses from the drop in NewAmsterdam Pharma's long position.

The idea behind Alto Neuroscience, and NewAmsterdam Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.